Beyond Air, Inc. (XAIR): Price and Financial Metrics
XAIR Price/Volume Stats
|Current price||$2.83||52-week high||$9.28|
|Prev. close||$2.97||52-week low||$2.55|
|Day high||$3.08||Avg. volume||406,692|
|50-day MA||$3.29||Dividend yield||N/A|
|200-day MA||$5.31||Market Cap||89.74M|
XAIR Stock Price Chart Interactive Chart >
Beyond Air, Inc. (XAIR) Company Bio
Beyond Air, Inc. operates as a medical device and biopharmaceutical company. The Company focuses on the discovery and development of a nitric oxide formulation and delivery systems to treat various respiratory diseases. Beyond Air serves patients and customers in the United States and Israel.
XAIR Latest News Stream
|Loading, please wait...|
XAIR Latest Social Stream
View Full XAIR Social Stream
Latest XAIR News From Around the Web
Below are the latest news stories about BEYOND AIR INC that investors may wish to consider to help them evaluate XAIR as an investment opportunity.
Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder
New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor The slow-release formulation led to reversal of behavioral phenotypes and the nitrosative stress of the Shank3 mouse model of autism. GARDEN CITY, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical co
Quite a few insiders have dramatically grown their holdings in Beyond Air, Inc. ( NASDAQ:XAIR ) over the past 12...
Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region
Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments based on net sales GARDEN CITY, New York, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patien
GARDEN CITY, N.Y., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air,
GARDEN CITY, N.Y., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in excess of $1 million in annual commercial LungFit PH contracts Secured up to $40 million in debt financing from Avenue Capital Reached agreement with FDA to run a U.S. clinical study in patients hospitalized with viral community acquired pneumonia (VCAP), which will be performed in the 2023-24 winter sea
XAIR Price Returns